Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis
CONCLUSION: In the MSS model, we found that first-line therapy for advanced or recurrent endometrial cancer with P/L increased costs and worsened outcomes compared to C/T. In the MSI-high model, P/L improved survival and QALYs compared to C/T but was not cost-effective at the current cost of the drugs.PMID:34103196 | DOI:10.1016/j.ygyno.2021.05.038 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Sarah A Ackroyd Elbert S Huang Katherine C Kurnit Nita K Lee Source Type: research

Prospective analysis of circulating metabolites and endometrial cancer risk
CONCLUSION: These findings suggest that variation in levels of glycine, serine, SM C18:0 and free carnitine may represent specific pathways linked to endometrial cancer development. If causal, these pathways may offer novel targets for endometrial cancer prevention.PMID:34099314 | DOI:10.1016/j.ygyno.2021.06.001 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 8, 2021 Category: Cancer & Oncology Authors: Laure Dossus Eirini Kouloura Carine Biessy Vivian Viallon Alexandros P Siskos Niki Dimou Sabina Rinaldi Melissa A Merritt Naomi Allen Renee Fortner Rudolf Kaaks Elisabete Weiderpass Inger T Gram Joseph A Rothwell Lucie L écuyer Gianluca Severi Matthias B Source Type: research

Trends and geographic variation in women's representation as principal investigators (PI) in phase 3 gynecologic oncology clinical trials
CONCLUSIONS: Women's representation as PIs in clinical trials has increased in the last decade. Trials funded by multiple sources outside of Asia have the highest proportion of PIs who are women. These trends may represent ongoing leadership and mentorship opportunities for women gynecologic oncologists.PMID:34099315 | DOI:10.1016/j.ygyno.2021.05.037 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 8, 2021 Category: Cancer & Oncology Authors: Jessica Jou Allison Brodsky Lindsey Charo Pratibha Binder Cheryl Saenz Ramez N Eskander Michael McHale Steve Plaxe Source Type: research

Prospective analysis of circulating metabolites and endometrial cancer risk
CONCLUSION: These findings suggest that variation in levels of glycine, serine, SM C18:0 and free carnitine may represent specific pathways linked to endometrial cancer development. If causal, these pathways may offer novel targets for endometrial cancer prevention.PMID:34099314 | DOI:10.1016/j.ygyno.2021.06.001 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 8, 2021 Category: Cancer & Oncology Authors: Laure Dossus Eirini Kouloura Carine Biessy Vivian Viallon Alexandros P Siskos Niki Dimou Sabina Rinaldi Melissa A Merritt Naomi Allen Renee Fortner Rudolf Kaaks Elisabete Weiderpass Inger T Gram Joseph A Rothwell Lucie L écuyer Gianluca Severi Matthias B Source Type: research

Trends and geographic variation in women's representation as principal investigators (PI) in phase 3 gynecologic oncology clinical trials
CONCLUSIONS: Women's representation as PIs in clinical trials has increased in the last decade. Trials funded by multiple sources outside of Asia have the highest proportion of PIs who are women. These trends may represent ongoing leadership and mentorship opportunities for women gynecologic oncologists.PMID:34099315 | DOI:10.1016/j.ygyno.2021.05.037 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 8, 2021 Category: Cancer & Oncology Authors: Jessica Jou Allison Brodsky Lindsey Charo Pratibha Binder Cheryl Saenz Ramez N Eskander Michael McHale Steve Plaxe Source Type: research

Risk of venous thromboembolism for ovarian cancer patients during first-line therapy after implementation of an Enhanced Recovery After Surgery (ERAS) protocol
CONCLUSION: With implementation of an ERAS protocol, only 1 in 46 patients experienced a VTE within 30 days after surgery. However, overall VTE occurred in 1 in 16 patients during first-line therapy. Strategies to further reduce VTE risk, especially during neoadjuvant chemotherapy and surveillance, should be investigated.PMID:34092412 | DOI:10.1016/j.ygyno.2021.05.032 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 7, 2021 Category: Cancer & Oncology Authors: Sue Li Alexandra S Bercow Michele Falzone Rajeshwari Kalyanaraman Michael J Worley Colleen M Feltmate Andrea Pelletier Kevin M Elias Source Type: research

Risk of secondary malignancies in ovarian cancer survivors: 52,680 patients analyzed with over 40 years of follow-up
Gynecol Oncol. 2021 Jun 3:S0090-8258(21)00440-6. doi: 10.1016/j.ygyno.2021.05.034. Online ahead of print.ABSTRACTOBJECTIVE: Survivors of ovarian cancer are at risk of developing a secondary malignancy (SM). We sought to evaluate the risk of developing SM, stratified by treatment modality.METHODS: Standardized incidence ratios (SIR, observed-to-expected [O/E] ratio) were assessed in 52,680 patients diagnosed with ovarian cancer between 1975 and 2016 in the National Cancer Institute's Surveillance, Epidemiology, and End Results Program.RESULTS: Of the 52,680 patients, 3366 patients (6.4%) developed SM, which was more than th...
Source: Gynecologic Oncology - June 7, 2021 Category: Cancer & Oncology Authors: Anthony C Casper Matthew W Parsons Jonathan Chipman Lindsay M Burt Gita Suneja Kathryn A Maurer David K Gaffney Source Type: research

Risk of venous thromboembolism for ovarian cancer patients during first-line therapy after implementation of an Enhanced Recovery After Surgery (ERAS) protocol
CONCLUSION: With implementation of an ERAS protocol, only 1 in 46 patients experienced a VTE within 30 days after surgery. However, overall VTE occurred in 1 in 16 patients during first-line therapy. Strategies to further reduce VTE risk, especially during neoadjuvant chemotherapy and surveillance, should be investigated.PMID:34092412 | DOI:10.1016/j.ygyno.2021.05.032 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 7, 2021 Category: Cancer & Oncology Authors: Sue Li Alexandra S Bercow Michele Falzone Rajeshwari Kalyanaraman Michael J Worley Colleen M Feltmate Andrea Pelletier Kevin M Elias Source Type: research

Risk of secondary malignancies in ovarian cancer survivors: 52,680 patients analyzed with over 40 years of follow-up
Gynecol Oncol. 2021 Jun 3:S0090-8258(21)00440-6. doi: 10.1016/j.ygyno.2021.05.034. Online ahead of print.ABSTRACTOBJECTIVE: Survivors of ovarian cancer are at risk of developing a secondary malignancy (SM). We sought to evaluate the risk of developing SM, stratified by treatment modality.METHODS: Standardized incidence ratios (SIR, observed-to-expected [O/E] ratio) were assessed in 52,680 patients diagnosed with ovarian cancer between 1975 and 2016 in the National Cancer Institute's Surveillance, Epidemiology, and End Results Program.RESULTS: Of the 52,680 patients, 3366 patients (6.4%) developed SM, which was more than th...
Source: Gynecologic Oncology - June 7, 2021 Category: Cancer & Oncology Authors: Anthony C Casper Matthew W Parsons Jonathan Chipman Lindsay M Burt Gita Suneja Kathryn A Maurer David K Gaffney Source Type: research

Non-exenterative surgical management of recurrent endometrial carcinoma
Gynecol Oncol. 2021 Jun 2:S0090-8258(21)00426-1. doi: 10.1016/j.ygyno.2021.05.020. Online ahead of print.ABSTRACTOBJECTIVE: To examine the role of non-exenterative secondary cytoreductive surgery (SCS) compared with non-surgical treatments and identify predictors of improved survival for patients with recurrent endometrial cancer (EC).METHODS: All patients undergoing primary surgical management for EC 1/1/2009-12/31/2017 who subsequently developed recurrence were retrospectively identified. Survival was determined from date of diagnosis of first recurrence to last follow-up and estimated using Kaplan-Meier method. Differen...
Source: Gynecologic Oncology - June 6, 2021 Category: Cancer & Oncology Authors: Lea A Moukarzel Kenya F Braxton Quin C Zhou Silvana Pedra Nobre Alexia Iasonos Kaled M Alektiar William P Tew Nadeem R Abu-Rustum Mario M Leitao Dennis S Chi Jennifer J Mueller Source Type: research

Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review
Gynecol Oncol. 2021 Jun 2:S0090-8258(21)00424-8. doi: 10.1016/j.ygyno.2021.05.018. Online ahead of print.ABSTRACTInhibitors of poly(ADP-ribose) polymerase (PARP) and angiogenesis have demonstrated single-agent activity in women with advanced ovarian cancer. Recent studies have aimed to establish whether combination therapy can augment the response seen with PARP inhibitors or antiangiogenic agents alone. This review provides an overview of PARP inhibitors and antiangiogenics as monotherapy in women with advanced ovarian cancer, explores potential mechanisms of action of PARP inhibitor and antiangiogenic combination treatme...
Source: Gynecologic Oncology - June 6, 2021 Category: Cancer & Oncology Authors: Angeles Alvarez Secord David M O'Malley Anil K Sood Shannon N Westin Joyce F Liu Source Type: research

Eligibility for cervical cancer screening exit: Comparison of a national and safety net cohort
CONCLUSIONS: Examining insurance claims in a national database and electronic medical records at a safety net institution led to remarkably similar findings: two thirds of women fail to qualify for screening exit. Additional steps to ensure eligibility prior to screening exit may be necessary to decrease preventable cervical cancers among women aged>65.CLINICAL TRIAL REGISTRATION: N/A.PMID:34090706 | DOI:10.1016/j.ygyno.2021.05.035 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 6, 2021 Category: Cancer & Oncology Authors: Jacqueline M Mills Jake R Morgan Amareen Dhaliwal Rebecca B Perkins Source Type: research

Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada
CONCLUSION: Postdiagnosis statin use was associated with improved survival among people with ovarian cancer. Given the consistency of this finding in the literature, we recommend a randomized clinical trial of statin use in people with ovarian cancer.PMID:34090707 | DOI:10.1016/j.ygyno.2021.05.021 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 6, 2021 Category: Cancer & Oncology Authors: Gillian E Hanley Paramdeep Kaur Andrew Berchuck Anne Chase Bronwyn Grout Cindy McKinnon Deurloo Malcolm Pike Jean Richardson Kathryn L Terry Penelope M Webb Leigh C Pearce Source Type: research

Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial
Gynecol Oncol. 2021 Jun 1:S0090-8258(21)00431-5. doi: 10.1016/j.ygyno.2021.05.025. Online ahead of print.ABSTRACTBACKGROUND: Treatment of patients with platinum resistant/refractory epithelial ovarian cancer (EOC) is an unmet need. We evaluated the role of oral metronomic therapy in this setting.PATIENTS AND METHODS: Between October 2017 and September 2019 seventy five patients with platinum resistant/refractory EOC were enrolled. Patients received oral etoposide (50 mg, day 1 to 14, cyclophosphamide 50 mg, day 1 to 28, every 4 weeks (Arm A, n = 38). Patients in Arm- B (n = 37) received Pazopanib (400 mg once daily) in add...
Source: Gynecologic Oncology - June 5, 2021 Category: Cancer & Oncology Authors: Aparna Sharma Mayank Singh Ravi Chauhan Prabhat Singh Malik Sachin Khurana Sandeep Mathur Sunesh Kumar Vishnubhatla Sreenivas Lalit Kumar Source Type: research

Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary
CONCLUSION: Findings from our study are foundational towards the development of immune classifiers and biomarkers of response to immune checkpoint blockade therapy in CCOC.PMID:34088514 | DOI:10.1016/j.ygyno.2021.05.010 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 5, 2021 Category: Cancer & Oncology Authors: Rachel Sue-A-Quan Palak G Patel Noor Shakfa May-Phyo Nyi Nyi Afrakoma Afriyie-Asante Eun Young Kang Martin K öbel Madhuri Koti Source Type: research

Prognostic value of myometrial invasion and TCGA groups of endometrial carcinoma
Gynecol Oncol. 2021 Jun 1:S0090-8258(21)00435-2. doi: 10.1016/j.ygyno.2021.05.029. Online ahead of print.ABSTRACTBACKGROUND: 2021 ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma (EC) encourage molecular classification and propose a new prognostic risk stratification based on both pathologic and molecular features. Although deep myometrial invasion (DMI) has been considered as a crucial risk factor in EC, it is unclear if its prognostic value is independent from The Cancer Genome ATLAS (TCGA) groups.AIM: To assess if the prognostic value of DMI is independent from the TCGA groups in EC pa...
Source: Gynecologic Oncology - June 5, 2021 Category: Cancer & Oncology Authors: Antonio Raffone Antonio Travaglino Diego Raimondo Daniele Neola Federica Renzulli Angela Santoro Luigi Insabato Paolo Casadio Gian Franco Zannoni Fulvio Zullo Antonio Mollo Renato Seracchioli Source Type: research

Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial
Gynecol Oncol. 2021 Jun 1:S0090-8258(21)00431-5. doi: 10.1016/j.ygyno.2021.05.025. Online ahead of print.ABSTRACTBACKGROUND: Treatment of patients with platinum resistant/refractory epithelial ovarian cancer (EOC) is an unmet need. We evaluated the role of oral metronomic therapy in this setting.PATIENTS AND METHODS: Between October 2017 and September 2019 seventy five patients with platinum resistant/refractory EOC were enrolled. Patients received oral etoposide (50 mg, day 1 to 14, cyclophosphamide 50 mg, day 1 to 28, every 4 weeks (Arm A, n = 38). Patients in Arm- B (n = 37) received Pazopanib (400 mg once daily) in add...
Source: Gynecologic Oncology - June 5, 2021 Category: Cancer & Oncology Authors: Aparna Sharma Mayank Singh Ravi Chauhan Prabhat Singh Malik Sachin Khurana Sandeep Mathur Sunesh Kumar Vishnubhatla Sreenivas Lalit Kumar Source Type: research

Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary
CONCLUSION: Findings from our study are foundational towards the development of immune classifiers and biomarkers of response to immune checkpoint blockade therapy in CCOC.PMID:34088514 | DOI:10.1016/j.ygyno.2021.05.010 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 5, 2021 Category: Cancer & Oncology Authors: Rachel Sue-A-Quan Palak G Patel Noor Shakfa May-Phyo Nyi Nyi Afrakoma Afriyie-Asante Eun Young Kang Martin K öbel Madhuri Koti Source Type: research

Prognostic value of myometrial invasion and TCGA groups of endometrial carcinoma
Gynecol Oncol. 2021 Jun 1:S0090-8258(21)00435-2. doi: 10.1016/j.ygyno.2021.05.029. Online ahead of print.ABSTRACTBACKGROUND: 2021 ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma (EC) encourage molecular classification and propose a new prognostic risk stratification based on both pathologic and molecular features. Although deep myometrial invasion (DMI) has been considered as a crucial risk factor in EC, it is unclear if its prognostic value is independent from The Cancer Genome ATLAS (TCGA) groups.AIM: To assess if the prognostic value of DMI is independent from the TCGA groups in EC pa...
Source: Gynecologic Oncology - June 5, 2021 Category: Cancer & Oncology Authors: Antonio Raffone Antonio Travaglino Diego Raimondo Daniele Neola Federica Renzulli Angela Santoro Luigi Insabato Paolo Casadio Gian Franco Zannoni Fulvio Zullo Antonio Mollo Renato Seracchioli Source Type: research

Modified frailty index predicts postoperative complications in women with gynecologic cancer undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Gynecol Oncol. 2021 May 31:S0090-8258(21)00409-1. doi: 10.1016/j.ygyno.2021.05.013. Online ahead of print.ABSTRACTOBJECTIVE(S): To evaluate the impact of frailty on postoperative complications following cytoreductive surgery (CRS) with hyperthermic intra-peritoneal chemotherapy (HIPEC) in women with advanced or recurrent gynecologic cancer.METHODS: An IRB-approved single-institution prospective registry was queried for women who underwent CRS with HIPEC for advanced or recurrent gynecologic cancer from 1/1/2014-12/31/2020. Frailty was defined as a modified Frailty Index (mFI) score of ≥2. Logistic regression was used to...
Source: Gynecologic Oncology - June 4, 2021 Category: Cancer & Oncology Authors: Laura M Chambers Julia Chalif Meng Yao Anna Chichura Molly Morton Morgan Gruner Anthony B Costales Max Horowitz Danielle B Chau Roberto Vargas Peter G Rose Chad M Michener Robert Debernardo Source Type: research

FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring
CONCLUSIONS: FOXL2 mutant ctDNA was present in the majority of aGCT patients and TERT promoter mutant ctDNA has been identified in a smaller subset of patients. Both FOXL2 and TERT mutant ctDNA detection may have clinical value in disease monitoring.PMID:34083028 | DOI:10.1016/j.ygyno.2021.05.027 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 4, 2021 Category: Cancer & Oncology Authors: Jolijn W Groeneweg Joline F Roze Edith D J Peters Ferdinando Sereno Anna G J Brink Sterre T Paijens Hans W Nijman Hannah S van Meurs Luc R C W van Lonkhuijzen Jurgen M J Piek Christianne A R Lok Glen R Monroe Gijs W van Haaften Ronald P Zweemer Source Type: research

Long-term oncological outcomes and recurrence patterns in early-stage cervical cancer treated with minimally invasive versus abdominal radical hysterectomy: The Norwegian Radium Hospital experience
Gynecol Oncol. 2021 May 31:S0090-8258(21)00434-0. doi: 10.1016/j.ygyno.2021.05.028. Online ahead of print.ABSTRACTOBJECTIVE: To compare long-term oncological outcomes in early-stage cervical cancer (CC) patients treated with minimally invasive radical hysterectomy (MIRH) versus abdominal radical hysterectomy (ARH), with a focus on recurrence patterns, tumor sizes, and conization.METHODS: This single-institution, retrospective study consisted of stage IA1-IB1 (FIGO 2009) squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma of the cervix, who underwent radical hysterectomy between 2000 and 2017.RESULTS: Of th...
Source: Gynecologic Oncology - June 4, 2021 Category: Cancer & Oncology Authors: Bilal M Sert Gunnar B Kristensen Andreas Kleppe Anne D ørum Source Type: research

Modified frailty index predicts postoperative complications in women with gynecologic cancer undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Gynecol Oncol. 2021 May 31:S0090-8258(21)00409-1. doi: 10.1016/j.ygyno.2021.05.013. Online ahead of print.ABSTRACTOBJECTIVE(S): To evaluate the impact of frailty on postoperative complications following cytoreductive surgery (CRS) with hyperthermic intra-peritoneal chemotherapy (HIPEC) in women with advanced or recurrent gynecologic cancer.METHODS: An IRB-approved single-institution prospective registry was queried for women who underwent CRS with HIPEC for advanced or recurrent gynecologic cancer from 1/1/2014-12/31/2020. Frailty was defined as a modified Frailty Index (mFI) score of ≥2. Logistic regression was used to...
Source: Gynecologic Oncology - June 4, 2021 Category: Cancer & Oncology Authors: Laura M Chambers Julia Chalif Meng Yao Anna Chichura Molly Morton Morgan Gruner Anthony B Costales Max Horowitz Danielle B Chau Roberto Vargas Peter G Rose Chad M Michener Robert Debernardo Source Type: research

FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring
CONCLUSIONS: FOXL2 mutant ctDNA was present in the majority of aGCT patients and TERT promoter mutant ctDNA has been identified in a smaller subset of patients. Both FOXL2 and TERT mutant ctDNA detection may have clinical value in disease monitoring.PMID:34083028 | DOI:10.1016/j.ygyno.2021.05.027 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 4, 2021 Category: Cancer & Oncology Authors: Jolijn W Groeneweg Joline F Roze Edith D J Peters Ferdinando Sereno Anna G J Brink Sterre T Paijens Hans W Nijman Hannah S van Meurs Luc R C W van Lonkhuijzen Jurgen M J Piek Christianne A R Lok Glen R Monroe Gijs W van Haaften Ronald P Zweemer Source Type: research

Long-term oncological outcomes and recurrence patterns in early-stage cervical cancer treated with minimally invasive versus abdominal radical hysterectomy: The Norwegian Radium Hospital experience
Gynecol Oncol. 2021 May 31:S0090-8258(21)00434-0. doi: 10.1016/j.ygyno.2021.05.028. Online ahead of print.ABSTRACTOBJECTIVE: To compare long-term oncological outcomes in early-stage cervical cancer (CC) patients treated with minimally invasive radical hysterectomy (MIRH) versus abdominal radical hysterectomy (ARH), with a focus on recurrence patterns, tumor sizes, and conization.METHODS: This single-institution, retrospective study consisted of stage IA1-IB1 (FIGO 2009) squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma of the cervix, who underwent radical hysterectomy between 2000 and 2017.RESULTS: Of th...
Source: Gynecologic Oncology - June 4, 2021 Category: Cancer & Oncology Authors: Bilal M Sert Gunnar B Kristensen Andreas Kleppe Anne D ørum Source Type: research

Cervical testing beyond the screening target age - A register-based cohort study from Finland
CONCLUSION: Testing at older age was frequent with normal results, whereas only a small proportion of women with earlier abnormal results or irregular attendance were tested. The upper age limit of the national programme should be raised to 65 years, and the invitations thereafter should be targeted to selected high-risk groups.PMID:34074539 | DOI:10.1016/j.ygyno.2021.05.019 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 2, 2021 Category: Cancer & Oncology Authors: Natalie Keltto Aku Leivonen Maiju Pankakoski Tytti Sarkeala Sirpa Hein ävaara Ahti Anttila Source Type: research

Cervical testing beyond the screening target age - A register-based cohort study from Finland
CONCLUSION: Testing at older age was frequent with normal results, whereas only a small proportion of women with earlier abnormal results or irregular attendance were tested. The upper age limit of the national programme should be raised to 65 years, and the invitations thereafter should be targeted to selected high-risk groups.PMID:34074539 | DOI:10.1016/j.ygyno.2021.05.019 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 2, 2021 Category: Cancer & Oncology Authors: Natalie Keltto Aku Leivonen Maiju Pankakoski Tytti Sarkeala Sirpa Hein ävaara Ahti Anttila Source Type: research

OVPSYCH2: A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancer
CONCLUSIONS: CBT-based psychological support provided after chemotherapy did not significantly alter the spontaneously improving trajectory of depression scores at three months but caused a significant improvement in FOP. Our findings call for the routine implementation of FOP support for ovarian cancer patients.PMID:34059348 | DOI:10.1016/j.ygyno.2021.05.024 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 1, 2021 Category: Cancer & Oncology Authors: E Frangou G Bertelli S Love M J Mackean R M Glasspool C Fotopoulou A Cook S Nicum R Lord M Ferguson R L Roux M Martinez C Butcher N Hulbert-Williams L Howells S P Blagden Source Type: research

Evaluation of p16 < sup > INK4a < /sup > immunocytology and human papillomavirus (HPV) genotyping triage after primary HPV cervical cancer screening on self-samples in China
Gynecol Oncol. 2021 May 28:S0090-8258(21)00410-8. doi: 10.1016/j.ygyno.2021.05.014. Online ahead of print.ABSTRACTOBJECTIVE: Self-sampling for human papillomavirus (HPV) testing is an effective option to increase the cervical screening coverage. How to best triage HPV-positive self-samples remains controversial. Here, we evaluated the performance of a novel p16INK4a immunocytology approach (p16) and HPV genotyping in triaging HPV-positive self-samples.METHODS: A cohort of 73699 women were screened via SeqHPV assay on self-samples. HPV-positive women who met any sequential positive result of HPV16/18 or VIA or p16 were refe...
Source: Gynecologic Oncology - June 1, 2021 Category: Cancer & Oncology Authors: Fangbin Song Jerome L Belinson Peisha Yan Xia Huang Chun Wang Hui Du Xinfeng Qu Ruifang Wu Source Type: research

Oncologic outcomes in the era of modern radiation therapy using FIGO 2018 staging system for cervical cancer
This study aims to evaluate the oncologic outcomes and predictors of survival using FIGO 2018 staging in a cohort of patients treated in an era of high-precision image-guided radiotherapy.METHODS: We performed a retrospective cohort study of 216 adult cervical cancer patients treated with definitive chemoradiotherapy between 2010 and 2018. Eligible patients had non-metastatic cervical cancer treated at a single academic institution. All patients had pre-treatment MRI and CT/PET. Treatment protocol consisted of external beam intensity-modulated radiotherapy and 3D image-guided brachytherapy. Kaplan-Meier curves were used fo...
Source: Gynecologic Oncology - June 1, 2021 Category: Cancer & Oncology Authors: Melica Nourmoussavi Brodeur Romain Dejean Marie-Claude Beauchemin Vanessa Samou ëlian B éatrice Cormier Omar Moreira Bacha Thomas Warkus Maroie Barkati Source Type: research

OVPSYCH2: A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancer
CONCLUSIONS: CBT-based psychological support provided after chemotherapy did not significantly alter the spontaneously improving trajectory of depression scores at three months but caused a significant improvement in FOP. Our findings call for the routine implementation of FOP support for ovarian cancer patients.PMID:34059348 | DOI:10.1016/j.ygyno.2021.05.024 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 1, 2021 Category: Cancer & Oncology Authors: E Frangou G Bertelli S Love M J Mackean R M Glasspool C Fotopoulou A Cook S Nicum R Lord M Ferguson R L Roux M Martinez C Butcher N Hulbert-Williams L Howells S P Blagden Source Type: research

Evaluation of p16 < sup > INK4a < /sup > immunocytology and human papillomavirus (HPV) genotyping triage after primary HPV cervical cancer screening on self-samples in China
Gynecol Oncol. 2021 May 28:S0090-8258(21)00410-8. doi: 10.1016/j.ygyno.2021.05.014. Online ahead of print.ABSTRACTOBJECTIVE: Self-sampling for human papillomavirus (HPV) testing is an effective option to increase the cervical screening coverage. How to best triage HPV-positive self-samples remains controversial. Here, we evaluated the performance of a novel p16INK4a immunocytology approach (p16) and HPV genotyping in triaging HPV-positive self-samples.METHODS: A cohort of 73699 women were screened via SeqHPV assay on self-samples. HPV-positive women who met any sequential positive result of HPV16/18 or VIA or p16 were refe...
Source: Gynecologic Oncology - June 1, 2021 Category: Cancer & Oncology Authors: Fangbin Song Jerome L Belinson Peisha Yan Xia Huang Chun Wang Hui Du Xinfeng Qu Ruifang Wu Source Type: research

Oncologic outcomes in the era of modern radiation therapy using FIGO 2018 staging system for cervical cancer
This study aims to evaluate the oncologic outcomes and predictors of survival using FIGO 2018 staging in a cohort of patients treated in an era of high-precision image-guided radiotherapy.METHODS: We performed a retrospective cohort study of 216 adult cervical cancer patients treated with definitive chemoradiotherapy between 2010 and 2018. Eligible patients had non-metastatic cervical cancer treated at a single academic institution. All patients had pre-treatment MRI and CT/PET. Treatment protocol consisted of external beam intensity-modulated radiotherapy and 3D image-guided brachytherapy. Kaplan-Meier curves were used fo...
Source: Gynecologic Oncology - June 1, 2021 Category: Cancer & Oncology Authors: Melica Nourmoussavi Brodeur Romain Dejean Marie-Claude Beauchemin Vanessa Samou ëlian B éatrice Cormier Omar Moreira Bacha Thomas Warkus Maroie Barkati Source Type: research

Corrigendum to "Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial" [Gynecologic Oncology 161 (2021) 143-151]
Gynecol Oncol. 2021 May 27:S0090-8258(21)00422-4. doi: 10.1016/j.ygyno.2021.05.016. Online ahead of print.NO ABSTRACTPMID:34053746 | DOI:10.1016/j.ygyno.2021.05.016 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 31, 2021 Category: Cancer & Oncology Authors: Monika Janda Kristy P Robledo Val Gebski Jane E Armes Michelle Alizart Donal Brennan Margaret Cummings Chen Chen Yee Leung Peter Sykes Orla McNally Martin K Oehler None GraemeWalker Andrea Garrett Amy Tang Russell Land James L Nicklin Naven Chetty Lewis C Source Type: research

The feasibility of folate receptor alpha- and HER2-targeted intraoperative fluorescence-guided cytoreductive surgery in women with epithelial ovarian cancer: A systematic review
CONCLUSION: FGCS targeting either HER2 or FRα appears to be feasible in both EOC animal models and patients with EOC. FGCS is a promising technique, but further research is warranted to validate these results and particularly study the survival benefit.PMID:34053747 | DOI:10.1016/j.ygyno.2021.05.017 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 31, 2021 Category: Cancer & Oncology Authors: J M de Jong J P Hoogendam A J A T Braat R P Zweemer C G Gerestein Source Type: research

The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens
CONCLUSIONS: These findings challenge the assumption that oral anti-cancer therapies are universally preferred by patients and demonstrate that there is no "one size fits all" regimen that is preferable to women with ovarian cancer when considering recurrence treatment regimens.PMID:34053748 | DOI:10.1016/j.ygyno.2021.05.022 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 31, 2021 Category: Cancer & Oncology Authors: Laura J Havrilesky Amelia L Scott Brittany A Davidson Angeles Alvarez Secord Jui-Chen Yang F Reed Johnson Juan Marcos Gonzalez Shelby D Reed Source Type: research

Corrigendum to "Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial" [Gynecologic Oncology 161 (2021) 143-151]
Gynecol Oncol. 2021 May 27:S0090-8258(21)00422-4. doi: 10.1016/j.ygyno.2021.05.016. Online ahead of print.NO ABSTRACTPMID:34053746 | DOI:10.1016/j.ygyno.2021.05.016 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 31, 2021 Category: Cancer & Oncology Authors: Monika Janda Kristy P Robledo Val Gebski Jane E Armes Michelle Alizart Donal Brennan Margaret Cummings Chen Chen Yee Leung Peter Sykes Orla McNally Martin K Oehler None GraemeWalker Andrea Garrett Amy Tang Russell Land James L Nicklin Naven Chetty Lewis C Source Type: research

The feasibility of folate receptor alpha- and HER2-targeted intraoperative fluorescence-guided cytoreductive surgery in women with epithelial ovarian cancer: A systematic review
CONCLUSION: FGCS targeting either HER2 or FRα appears to be feasible in both EOC animal models and patients with EOC. FGCS is a promising technique, but further research is warranted to validate these results and particularly study the survival benefit.PMID:34053747 | DOI:10.1016/j.ygyno.2021.05.017 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 31, 2021 Category: Cancer & Oncology Authors: J M de Jong J P Hoogendam A J A T Braat R P Zweemer C G Gerestein Source Type: research

The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens
CONCLUSIONS: These findings challenge the assumption that oral anti-cancer therapies are universally preferred by patients and demonstrate that there is no "one size fits all" regimen that is preferable to women with ovarian cancer when considering recurrence treatment regimens.PMID:34053748 | DOI:10.1016/j.ygyno.2021.05.022 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 31, 2021 Category: Cancer & Oncology Authors: Laura J Havrilesky Amelia L Scott Brittany A Davidson Angeles Alvarez Secord Jui-Chen Yang F Reed Johnson Juan Marcos Gonzalez Shelby D Reed Source Type: research

PARP inhibitor associated treatment related myeloid neoplasms: What was a "Rare" complication may be less so
Gynecol Oncol. 2021 Jun;161(3):639-641. doi: 10.1016/j.ygyno.2021.05.006.NO ABSTRACTPMID:34049655 | DOI:10.1016/j.ygyno.2021.05.006 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 29, 2021 Category: Cancer & Oncology Authors: Kathleen N Moore Source Type: research

PARP inhibitor associated treatment related myeloid neoplasms: What was a "Rare" complication may be less so
Gynecol Oncol. 2021 Jun;161(3):639-641. doi: 10.1016/j.ygyno.2021.05.006.NO ABSTRACTPMID:34049655 | DOI:10.1016/j.ygyno.2021.05.006 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 29, 2021 Category: Cancer & Oncology Authors: Kathleen N Moore Source Type: research

Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis
CONCLUSIONS: Proper patient selection for tertiary cytoreduction is essential. Those who achieve CGR likely derive the greatest benefit from tertiary surgery. Platinum sensitivity and prolonged TFI are also associated with improved DSS. Patients with HGSOC and single-site recurrence who were ≥2 years out from secondary cytoreduction had the longest DSS.PMID:34045053 | DOI:10.1016/j.ygyno.2021.05.015 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 28, 2021 Category: Cancer & Oncology Authors: Beryl L Manning-Geist Dennis S Chi Kara Long Roche Oliver Zivanovic Yukio Sonoda Ginger J Gardner Roisin E O'Cearbhaill Nadeem R Abu-Rustum Mario M Leitao Source Type: research

Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis
CONCLUSIONS: Proper patient selection for tertiary cytoreduction is essential. Those who achieve CGR likely derive the greatest benefit from tertiary surgery. Platinum sensitivity and prolonged TFI are also associated with improved DSS. Patients with HGSOC and single-site recurrence who were ≥2 years out from secondary cytoreduction had the longest DSS.PMID:34045053 | DOI:10.1016/j.ygyno.2021.05.015 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 28, 2021 Category: Cancer & Oncology Authors: Beryl L Manning-Geist Dennis S Chi Kara Long Roche Oliver Zivanovic Yukio Sonoda Ginger J Gardner Roisin E O'Cearbhaill Nadeem R Abu-Rustum Mario M Leitao Source Type: research

State of the science: Uterine carcinosarcomas: From pathology to practice
CONCLUSION: Ongoing endometrial cancer clinical trials now include UCS patients. In combination with advances in molecular profiling, this will provide patients with UCS improved therapeutic options. Until that time, surgical resection and traditional cytotoxic chemotherapy remains standard of care.PMID:34030871 | DOI:10.1016/j.ygyno.2021.05.003 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 25, 2021 Category: Cancer & Oncology Authors: Michael D Toboni Erin K Crane Jubilee Brown Alexander Shushkevich Sarah Chiang Brian M Slomovitz Douglas A Levine Sean C Dowdy Ann Klopp Matthew A Powell Premal H Thaker Source Type: research

State of the science: Uterine carcinosarcomas: From pathology to practice
CONCLUSION: Ongoing endometrial cancer clinical trials now include UCS patients. In combination with advances in molecular profiling, this will provide patients with UCS improved therapeutic options. Until that time, surgical resection and traditional cytotoxic chemotherapy remains standard of care.PMID:34030871 | DOI:10.1016/j.ygyno.2021.05.003 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 25, 2021 Category: Cancer & Oncology Authors: Michael D Toboni Erin K Crane Jubilee Brown Alexander Shushkevich Sarah Chiang Brian M Slomovitz Douglas A Levine Sean C Dowdy Ann Klopp Matthew A Powell Premal H Thaker Source Type: research

State of the science: Uterine carcinosarcomas: From pathology to practice
CONCLUSION: Ongoing endometrial cancer clinical trials now include UCS patients. In combination with advances in molecular profiling, this will provide patients with UCS improved therapeutic options. Until that time, surgical resection and traditional cytotoxic chemotherapy remains standard of care.PMID:34030871 | DOI:10.1016/j.ygyno.2021.05.003 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 25, 2021 Category: Cancer & Oncology Authors: Michael D Toboni Erin K Crane Jubilee Brown Alexander Shushkevich Sarah Chiang Brian M Slomovitz Douglas A Levine Sean C Dowdy Ann Klopp Matthew A Powell Premal H Thaker Source Type: research

Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database
CONCLUSION: PARPis increased the risk of pneumonitis that can result in serious outcomes and tend to occur early. Early recognition and management of PARPi-pneumonitis is of vital importance in clinical practice. The mechanisms and risk factors should be studied further to improve clinical understanding and innovative treatment strategies for these diseases.PMID:34023129 | DOI:10.1016/j.ygyno.2021.05.012 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 23, 2021 Category: Cancer & Oncology Authors: Zhuo Ma Ximu Sun Zhixia Zhao Wenchao Lu Qixiang Guo Shihao Wang Jiwen You Yuhui Zhang Lihong Liu Source Type: research

Neuroendocrine tumors of the gynecologic tract update
Gynecol Oncol. 2021 May 19:S0090-8258(21)00359-0. doi: 10.1016/j.ygyno.2021.04.039. Online ahead of print.NO ABSTRACTPMID:34023130 | DOI:10.1016/j.ygyno.2021.04.039 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 23, 2021 Category: Cancer & Oncology Authors: I Winer C Kim P Gehrig Source Type: research

Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis
CONCLUSIONS: Reported rates of genetic testing for people with ovarian cancer remain well below the goal of universal testing. Interventions such as mainstreaming can improve testing uptake. Strategies aimed at improving utilization of genetic services should consider existing disparities in race and insurance status.PMID:34023131 | DOI:10.1016/j.ygyno.2021.05.011 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 23, 2021 Category: Cancer & Oncology Authors: Jenny Lin Ravi N Sharaf Rachel Saganty Danyal Ahsan Julia Feit Andrea Khoury Hannah Bergeron Eloise Chapman-Davis Evelyn Cantillo Kevin Holcomb Stephanie V Blank Ying Liu Charlene Thomas Paul J Christos Drew N Wright Steven Lipkin Kenneth Offit Melissa K Source Type: research

Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database
CONCLUSION: PARPis increased the risk of pneumonitis that can result in serious outcomes and tend to occur early. Early recognition and management of PARPi-pneumonitis is of vital importance in clinical practice. The mechanisms and risk factors should be studied further to improve clinical understanding and innovative treatment strategies for these diseases.PMID:34023129 | DOI:10.1016/j.ygyno.2021.05.012 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 23, 2021 Category: Cancer & Oncology Authors: Zhuo Ma Ximu Sun Zhixia Zhao Wenchao Lu Qixiang Guo Shihao Wang Jiwen You Yuhui Zhang Lihong Liu Source Type: research